|1.||Gillies, Stephen D: 4 articles (12/2011 - 05/2004)|
|2.||Connor, Joseph P: 2 articles (01/2013 - 05/2004)|
|3.||Felder, Mildred: 2 articles (01/2013 - 05/2004)|
|4.||Harter, Josephine: 2 articles (01/2013 - 05/2004)|
|5.||Buhtoiarov, Ilia N: 2 articles (12/2011 - 08/2009)|
|6.||Sondel, Paul M: 2 articles (12/2011 - 08/2009)|
|7.||Lewis, Lionel D: 1 article (01/2013)|
|8.||Stewart, Sarah: 1 article (01/2013)|
|9.||Lewis, Nancy L: 1 article (01/2013)|
|10.||Komarnitsky, Philip B: 1 article (01/2013)|
08/01/2009 - "tumors with RFA and huKS-IL2 resulted in significantly greater tumor growth suppression and enhanced survival compared with mice treated with RFA or huKS-IL2 alone. "
08/01/2009 - "These results show that the addition of huKS-IL2 to RFA significantly enhances the antitumor response in this murine model, resulting in complete tumor resolution and induction of immunologic memory."
08/01/2009 - "Flow cytometry analysis of tumor-reactive T cells from mice with complete tumor resolution showed that treatment with RFA and huKS-IL2 resulted in a greater proportion of cytokine-producing CD4 T cells and CD8 T cells compared with mice treated with RFA or huKS-IL2 alone. "
08/01/2009 - "Treatment of a tumor with RFA and intratumoral huKS-IL2 also showed antitumor effects against a distant untreated tumor. "
08/01/2009 - "When subtherapeutic regimens of RFA or huKS-IL2 were used, tumors progressed in all treated mice. "
|2.||Prostatic Neoplasms (Prostate Cancer)
05/01/2004 - "These data demonstrate that the novel immunocytokine EMD 273066 is well tolerated at doses above a level of observed systemic biologic activity in patients with androgen-independent prostate cancer."
05/01/2004 - "Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer."
05/01/2004 - "This phase 1 clinical trial was conducted to evaluate the safety and to determine the maximum tolerated dose (MTD) of the immunocytokine EMD 273066 huKS-IL2 and, secondarily, to assess its pharmacokinetics, immunogenic potential, and immunologic activity in patients with androgen-independent prostate cancer (n = 22). "
08/01/2009 - "Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma."
08/01/2009 - "In this preclinical study, we sought to enhance the antitumor effect of RFA by combining it with huKS-IL2 immunocytokine [tumor-specific monoclonal antibody fused to interleukin-2 (IL2)] in mice bearing CT26-KS colon adenocarcinoma. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
12/01/2011 - "NK cells isolated from the peritoneal environment of ovarian cancer patients, known to be impaired in mediating ADCC, bind to huKS-IL2 via CD25. "
05/01/2004 - "Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer."
05/01/2004 - "To determine the potential therapeutic use of huKS-IL2 in ovarian cancer, the authors evaluated the expression of EpCAM in these cancers and investigated the effects of huKS-IL2 on peritoneal white blood cells and peripheral blood mononuclear cells from women with ovarian cancer. "
|3.||tumor-associated antigen GA733
|7.||Interleukin-2 Receptors (IL 2 Receptor)
|1.||Drug Therapy (Chemotherapy)